Moderna Inc (MRNA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $90.38B
Last updated: Nov 17, 2026 at 11:06 AM ET
Moderna Inc (MRNA) Financials: Revenue, Profit and Cash Flow
Moderna reported revenue of $1.94B for the fiscal year ended Dec 31, 2025, down 39.9% from the year before. That year, net income was -$2.82B with a net margin of -145.2%, operating cash flow was -$1.87B and free cash flow was -$2.06B. The quarter ended Sep 30, 2026 had revenue of $1.31B and net income of $162.00M.
Revenue and Margins
Over the 9 years to Dec 2025, revenue grew from $108.40M, a compound annual rate of 37.8%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $1.94B | -39.9% | 55.3% | -158.1% | -145.2% |
| Dec 2024 | $3.24B | -52.7% | 54.8% | -121.9% | -110.0% |
| Dec 2023 | $6.85B | -64.4% | 31.5% | -61.9% | -68.8% |
| Dec 2022 | $19.26B | +4.3% | 71.9% | 48.9% | 43.4% |
| Dec 2021 | $18.47B | +2200.2% | 85.8% | 72.0% | 66.1% |
| Dec 2020 | $803.00M | +1238.3% | 99.0% | -95.0% | -93.0% |
| Dec 2019 | $60.00M | -55.6% | 100.0% | -910.0% | -856.7% |
| Dec 2018 | $135.07M | -34.4% | 100.0% | -306.0% | -284.8% |
| Dec 2017 | $205.82M | +89.9% | 100.0% | -130.9% | -124.3% |
| Dec 2016 | $108.40M | N/A | 100.0% | -206.4% | -199.5% |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.94B | $3.24B | $6.85B | $19.26B | $18.47B | $803.00M | $60.00M | $135.07M | $205.82M | $108.40M |
| Cost of revenue | $868.00M | $1.46B | $4.69B | $5.42B | $2.62B | $8.00M | $0 | $0 | $0 | $0 |
| Gross profit | $1.08B | $1.77B | $2.15B | $13.85B | $15.85B | $795.00M | $60.00M | $135.07M | $205.82M | $108.40M |
| Research and development | $3.13B | $4.54B | $4.84B | $3.29B | $1.99B | $1.37B | $496.00M | $454.08M | $410.46M | $274.72M |
| Operating income | -$3.07B | -$3.94B | -$4.24B | $9.42B | $13.30B | -$763.00M | -$546.00M | -$413.27M | -$269.36M | -$223.77M |
| Net income | -$2.82B | -$3.56B | -$4.71B | $8.36B | $12.20B | -$747.00M | -$514.00M | -$384.73M | -$255.92M | -$216.21M |
| EBITDA | -$2.93B | -$3.94B | -$3.80B | $9.75B | $13.55B | -$728.00M | -$527.00M | -$388.44M | -$249.61M | -$208.89M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.31B | $145.00M | $389.00M | $678.00M | $1.02B | $142.00M | $108.00M | $966.00M | $1.86B | $241.00M | $167.00M | $2.81B |
| Gross profit | $995.00M | $52.00M | -$566.00M | $226.00M | $809.00M | $23.00M | $18.00M | $227.00M | $1.35B | $126.00M | $71.00M | $1.88B |
| Operating income | $130.00M | -$815.00M | -$1.39B | -$857.00M | -$260.00M | -$907.00M | -$1.05B | -$1.25B | -$70.00M | -$1.36B | -$1.27B | $6.00M |
| Net income | $162.00M | -$782.00M | -$1.34B | -$826.00M | -$200.00M | -$825.00M | -$971.00M | -$1.12B | $13.00M | -$1.28B | -$1.18B | $217.00M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded long-term debt of $590.00M by $2.00B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $12.34B | $14.14B | $18.43B | $25.86B | $24.67B | $7.34B | $1.59B | $2.02B | $1.08B | $1.42B |
| Current assets | $6.54B | $8.10B | $10.32B | $13.43B | $16.07B | $6.30B | $1.13B | $37.05M | $783.22M | $1.09B |
| Cash and equivalents | $2.60B | $1.93B | $2.91B | $3.21B | $6.85B | $2.62B | $235.88M | $658.36M | $134.86M | $50.08M |
| Total liabilities | $3.69B | $3.24B | $4.57B | $6.74B | $10.52B | $4.78B | $414.61M | $354.99M | $459.19M | $575.31M |
| Short-term debt | N/A | $37.00M | $25.00M | $196.00M | $211.00M | $30.00M | $67.65M | $79.07M | $72.72M | $25.05M |
| Long-term debt | $590.00M | $0 | N/A | N/A | N/A | N/A | N/A | N/A | $15.69M | $12.50M |
| Shareholder equity | $8.65B | $10.90B | $13.85B | $19.12B | $14.14B | $2.56B | $1.17B | -$982.43M | -$551.37M | $841.85M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $13.47B | $10.96B | $11.49B | $12.34B | $12.13B | $12.01B | $12.70B | $14.14B | $15.80B | $15.68B | $16.73B | $18.43B |
| Total liabilities | $6.63B | $4.20B | $4.08B | $3.69B | $2.81B | $2.61B | $2.64B | $3.24B | $3.88B | $3.97B | $3.91B | $4.57B |
| Cash and equivalents | $1.20B | $1.72B | $1.91B | $2.60B | $1.13B | $1.28B | $1.62B | $1.93B | $1.64B | $2.48B | $2.05B | $2.91B |
| Shareholder equity | $6.84B | $6.76B | $7.41B | $8.65B | $9.33B | $9.40B | $10.07B | $10.90B | $11.93B | $11.71B | $12.82B | $13.85B |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.87B | -$3.00B | -$3.12B | $4.98B | $13.62B | $2.03B | -$459.00M | -$330.87M | -$331.48M | $66.73M |
| Capital expenditures | $192.00M | $1.05B | $707.00M | $400.00M | $284.00M | $68.00M | $32.00M | $105.77M | $58.40M | $33.14M |
| Free cash flow | -$2.06B | -$4.05B | -$3.83B | $4.58B | $13.34B | $1.96B | -$491.00M | -$436.63M | -$389.88M | $33.59M |
| Dividends paid | N/A | N/A | $270.00M | $184.00M | $124.00M | $7.04M | N/A | N/A | $1.48M | $633.00K |
| Share repurchases | $2.00M | $0 | $1.15B | $3.33B | $857.00M | $0 | $0 | N/A | N/A | N/A |
| Investing cash flow | $1.95B | $1.95B | $4.21B | -$5.18B | -$8.52B | -$1.67B | -$15.00M | -$373.09M | $417.36M | -$648.61M |
| Financing cash flow | $593.00M | $56.00M | -$1.38B | -$3.45B | -$873.00M | $2.03B | $52.00M | $1.23B | $168.00K | $472.91M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.56B | -$526.00M | -$630.00M | $930.00M | -$847.00M | -$919.00M | -$1.04B | $825.00M | -$1.57B | -$1.27B | -$989.00M | $622.00M |
| Capital expenditures | $47.00M | $37.00M | $62.00M | $39.00M | $33.00M | $3.00M | $117.00M | $522.00M | $151.00M | $182.00M | $196.00M | $220.00M |
| Free cash flow | -$1.61B | -$563.00M | -$692.00M | $891.00M | -$880.00M | -$922.00M | -$1.15B | $303.00M | -$1.72B | -$1.46B | -$1.19B | $402.00M |
Frequently Asked Questions About MRNA
What is Moderna's annual revenue?
Moderna reported revenue of $1.94B for the fiscal year ended Dec 31, 2025.
How fast is Moderna's revenue growing?
Revenue was down 39.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -53.4%.
Is Moderna profitable?
No. Moderna reported net income of -$2.82B for the fiscal year ended Dec 31, 2025, with a net margin of -145.2%.
How much free cash flow does MRNA generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$1.87B minus capital expenditures of $192.00M produced free cash flow of -$2.06B.
How much debt does Moderna have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $590.00M and cash and equivalents of $2.60B.
MRNA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors